Cited by 208Hepatitis B Virus StudiesIntramuscular injections and effectsCervical Cancer and HPV Research

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant.

Open access

Schillie, Sarah, Harris, Aaron, Link-Gelles, Ruth, Romero, José, Ward, John, Nelson, Noele·2018·MMWR Morbidity and Mortality Weekly Report

DOI 10.15585/mmwr.mm6715a5PMC PMC6191098

Open this paper in CoChat — free account Open PDF

Abstract

Hepatitis B (HepB) vaccination is the primary means of preventing infections and complications caused by hepatitis B virus (HBV). On February 21, 2018, the Advisory Committee on Immunization Practices (ACIP) recommended Heplisav-B (HepB-CpG), a yeast-derived vaccine prepared with a novel adjuvant, administered as a 2-dose series (0, 1 month) for use in persons aged ≥18 years. The ACIP Hepatitis Vaccines Work Group conducted a systematic review of the evidence, including data from four randomized controlled trials assessing prevention of HBV infection and six randomized controlled trials assessing adverse events in adults. Seroprotective antibody to hepatitis B surface antigen (anti-HBs) levels were achieved in 90.0%-100.0% of subjects receiving HepB-CpG (Dynavax Technologies Corporation), compared with 70.5%-90.2% of subjects receiving Engerix-B (GlaxoSmithKline Biologicals). The benefits of protection with 2 doses administered over 1 month make HepB-CpG an important option for prevention of HBV.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.15585/mmwr.mm6715a5

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices.
Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6701a1 · Cited by 815
Self-citation
Immunogenicity of a two-dose investigational hepatitis b vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults
Jackson, S., Lentino, J., Kopp, J., Murray, L., Ellison, W., Rhee, M., Shockey, G., Akella, L., Erby, K., Heyward, W. L., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.038 · Cited by 197
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
Halperin, S. A., Ward, B. J., Cooper, C., Predy, G., Díaz‐Mitoma, F., Dionne, M., Embreé, J., McGeer, A., Zickler, P., Moltz, K.-H., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.087 · Cited by 135
Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults
Halperin, S. A., Dobson, S., McNeil, S., Langley, J. M., Smith, B. R., McCall-Sani, R., Levitt, D., Nest, G. V., Gennevois, D., & Eiden, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.095 · Cited by 134
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age
Heyward, W. L., Kyle, M., Blumenau, J., Davis, M., Reisinger, K. S., Kabongo, M. L., Bennett, S. R., Janssen, R. S., Namini, H., & Martin, J. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.068 · Cited by 121
Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease
Janssen, R. S., Mangoo‐Karim, R., Pérgola, P. E., Girndt, M., Namini, H., Rahman, S., Bennett, S. R., Heyward, W. L., & Martin, J. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.067 · Cited by 81
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine
Sablan, B. P., Kim, D. J., Barzaga, N. G., Chow, W. C., Cho, M., Ahn, S. H., Hwang, S. G., Lee, J.-H., Namini, H., & Heyward, W. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.001 · Cited by 68
Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine
Halperin, S. A., Ward, B. J., Dionne, M. S., Langley, J. M., McNeil, S., Smith, B. R., MacKinnon‐Cameron, D., Heyward, W. L., & Martin, J. T. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24256 · Cited by 28
New framework (GRADE) for development of evidence-based recommendations by the Advisory Committee on Immunization Practices.
(2012) · PubMed · Cited by 20

Show all 9 references

Sorted by citations

Items 101–200 of 208

High Rates of Seroprotection to Hepatitis B After a Hepatitis B Challenge Dose in Previously Vaccinated Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy
Ley, D., Lazarus, S. G., Forati, A. M., Farraye, F. A., Smith, R. A., Hayney, M. S., & Caldera, F. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08527-1 · Cited by 8
Nucleic Acid Nanostructure Assisted Immune Modulation
Sun, X., & Liu, H. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01195 · Cited by 8
Recent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOV_S1_CTD of the S Protein
Gupta, A., Singh, A. P., Singh, V. K., & Sinha, R. P. (2023) · Viruses · doi:10.3390/v15061234 · Cited by 8
An Update on Adult Immunization
Kamath, V., Markanday, K., & Nivea, B. (2021) · APIK Journal of Internal Medicine · doi:10.4103/ajim.ajim_51_20 · Cited by 8
Evolving considerations for choice of hepatitis B vaccine
Surofchy, D. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89325 · Cited by 7
Cost-Effectiveness of an Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) in Patients With Inflammatory Bowel Disease
Corral, J. E., Kwon, J. Y., Caldera, F., Pungpapong, S., Spaulding, A., Borah, B. J., Moriarty, J. P., & Farraye, F. A. (2020) · Crohn s & Colitis 360 · doi:10.1093/crocol/otaa090 · Cited by 7
High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults
Chahine, E. B. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020935645 · Cited by 7
Approach to vaccinating the pediatric solid organ transplant candidate and recipient
Kao, C. M., & Michaels, M. G. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1271065 · Cited by 6
Hepatitis B Vaccination: A Remarkable Success Story That Must Continue
Lok, A. S.-F., Ward, J. W., Chang, H.-L., & Cohen, C. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.10.295 · Cited by 6
Self-citation
Abnormally primed CD8 T cells: The Achilles’ heel of CHB
Chen, X., Liu, X., Jiang, Y., Xia, N., Liu, C., & Luo, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1106700 · Cited by 6
Travel-Associated Infections & Diseases
Nemhauser, J. B. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197570944.003.0005 · Cited by 6
High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease
Hegde, Y. D., Lazarus, S. G., Farraye, F. A., Hollnagel, F., Hayney, M. S., & Caldera, F. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002098 · Cited by 6
Heplisav-B in Prior Hepatitis B Vaccine Nonresponders: A Case Series
Williams, A. L. (2021) · Military Medicine · doi:10.1093/milmed/usab397 · Cited by 6
Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination
Janssen, R. S., Bruxvoort, K. J., Jacobsen, S. J., Slezak, J. M., David, C., Hyer, R. N., & Poland, G. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.100 · Cited by 6
Optimizing Immunization Strategies in Adult Patients With Chronic Liver Disease and Liver Transplant Recipients.
Rolak, S. C., Said, A., German, M. N., Hayney, M. S., & Caldera, F. (2022) · PubMed Central · Cited by 5
Hepatitis B Vaccines
Ward, J. W., Wanlapakorn, N., Poovorawan, Y., & Shouval, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00027-x · Cited by 5
Self-citation
New Advances in Hepatitis B Vaccination for Adults
Huang, Q. D., & Lim, S. G. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0435-5 · Cited by 5
Challenges in Phase 4 post-licensure safety studies using real world data in the United States: Hepatitis B vaccine example
Bruxvoort, K. J., Sy, L. S., Ackerson, B. K., Slezak, J. M., Qian, L., Towner, W. J., Reynolds, K., Solano, Z., Carlson, C. M., & Jacobsen, S. J. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100101 · Cited by 5
Toll-like Receptor 9 Agonists as Adjuvants for Nanoparticle-Based Nicotine Vaccine
Hu, Y. Y., Smith, D., Frazier, E., Zhao, Z., & Zhang, C. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01153 · Cited by 5
Impaired anti-HBV vaccine response in non-cirrhotic chronic HCV is not overcome by double dose regimen: randomized control trial
Medeiros, R. P., Terrault, N. A., Mazo, D. F. D. C., de Oliveira, C. P. M. S., Dodge, J. L., Zitelli, P. M., Lopes, M. H., Carrilho, F. J., & Pessôa, M. G. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100891 · Cited by 5
Prevalence of hepatitis B virus infection and effects of service charges on notification among pregnant women attending antenatal care at General Hospital, Otukpo, Nigeria
Anejo-Okopi, J. A., Aju-Ameh, C. O., Agboola, O. O., Edegbene, A. O., Ujoh, J. A., Audu, O., Ochejele, S., Agbo, E. B., Odu, E., Abah, S. O., et al. (2023) · Annals of Medical Research and Practice · doi:10.25259/anmrp_14_2022 · Cited by 5
Screening of donors and recipients for infections prior to solid organ transplantation
Nanayakkara, D. D., & Schaenman, J. M. D. (2019) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000671 · Cited by 5
Modeling the impact of double dose vaccination and vertical transmission on hepatitis B with saturated incidence and optimal control
Ambika, & Sinha, A. K. (2025) · Franklin Open · doi:10.1016/j.fraope.2025.100379 · Cited by 4
Hepatitis B–CpG Vaccine Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders
Russ, R. K., Vandehei, H. M., Golovkina, M. I., Mogallapalli, H., Caldera, F., & Hayney, M. S. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae320 · Cited by 4
Adult Immunization Update
Sha, B. E. (2019) · JAMA · doi:10.1001/jama.2019.12739 · Cited by 4
Age-specific seroprotection after Hepatitis B virus vaccination among Korean American pediatric population in Queens, New York
Min, E., Min, J., & Kim, R. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2053404 · Cited by 4
The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines
Tulaeva, I., Lehmann, F., Goldmann, N., Dubovets, A. A., Trifonova, D., Tulaev, M., Cornelius, C., Weber, M., Focke‐Tejkl, M., Karaulov, A. V., et al. (2024) · Vaccines · doi:10.3390/vaccines12101123 · Cited by 4
Variable anti-HBs antibody titers in vaccinated birth cohorts – A cross-sectional population-based study
Istrate, A., Azoicăi, D., Almaş, A., & Rădulescu, A. L. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.027 · Cited by 4
Antigen stabilizing hydrogels based on cyclodextrins and polyethylene glycol act as type-2 adjuvants with suppressed local irritation
Hayashi, T., Nakagawa, F., Ohno, Y., Suzuki, Y., Ishiki, H., Onodera, R., Higashi, T., Shimamura, Y., Itou, H., Iwase, Y., et al. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.11.002 · Cited by 4
An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches
Thompson, K. M., Orenstein, W. A., & Hinman, A. R. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.04.044 · Cited by 4
Barriers Against Hepatitis B Vaccination in High-Risk Adults: A Cross-Sectional Study
Aslan, A. T., Şaşmazer, B., Ayar, Y., Duran, Z. C., & Akova, M. (2022) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2022.21257 · Cited by 3
Could eggshell membrane be an adjuvant for recombinant Hepatitis B vaccine?: A preliminary investigation
Joshua, P. E., Ilo, C. C., Ukachukwu, U. G., Odimegwu, D. C., Asomadu, R. O., & Ezeorba, T. P. C. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-023-00481-5 · Cited by 3
Immunizations in liver transplant candidates
Ley, D., & Musto, J. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000031 · Cited by 3
Post-marketing safety study to evaluate pregnancy outcomes among recipients of hepatitis B vaccines
Bruxvoort, K. J., Sy, L. S., Slezak, J. M., Ackerson, B. K., Qian, L., Qiu, S., Solano, Z., & Reynolds, K. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2397872 · Cited by 3
Vaccine effect of recombinant single-chain hemagglutinin protein as an antigen
Kawai, A., Yamamoto, Y., & Yoshioka, Y. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04301 · Cited by 3
Pharmacist led vaccination rates in opioid addicted obstetric patients
Forinash, A. B., Yancey, A. M., & Shyken, J. M. (2020) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1364 · Cited by 3
Hepatitis B vaccination response and safety in people living with HIV/AIDS receiving HepB-CpG series
Preininger, L., Kahal, D., & Szabo, S. M. (2021) · AIDS · doi:10.1097/qad.0000000000002813 · Cited by 3
Vaccines for Healthcare Personnel
Weber, D. J., & Shenoy, E. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00072-4 · Cited by 3
Chronic hepatitis B infection in healthcare personnel identified after nonresponse to hepatitis B vaccine: A report of 4 cases
Guynn, N., Ciccone, E. J., Sickbert-Bennett, E. E., & Weber, D. J. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.328 · Cited by 3
Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older — United States, 2019
Kim, D. K., & Hunter, P. H. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15336 · Cited by 3
Development of human mycoplasma vaccines: navigating the IL-17A paradox
Zhang, W., Li, T., & Guo, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1720943 · Cited by 2
Vaccination and safe living strategies for solid organ transplant candidates and recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Kumar, D., Avery, R. K., Danziger‐Isakov, L. A., Hall, V. G., Hanisch, B. R., Harris, C. E., Kates, O. S., Nam, H. H., Rolfe, R. J., & Kotton, C. N. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.07.033 · Cited by 2
Vaccine update: The latest recommendations from ACIP
Campos-Outcalt (2022) · The Journal of Family Practice · doi:10.12788/jfp.0362 · Cited by 2
Rapidly Evolving SARS-CoV-2: A Brief Review Regarding the Variants and their Effects on Vaccine Efficacies
Nawaz, S., Janiad, S., Fatima, A., Saleem, M., Fatima, U., & Ali, A. (2024) · Infectious Disorders - Drug Targets · doi:10.2174/0118715265271109231129112515 · Cited by 2
Posttransplant HBV Vaccine Compliance, Seroprotection, and Kinetics of Hepatitis B Surface Antibody in Thoracic Organ Transplant Recipients
Chiu, C., Sampathkumar, P., Brumble, L. M., Vikram, H. R., Watt, K. D., & Beam, E. N. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70015 · Cited by 2
Destabilising Effect of Class B CpG Adjuvants on Different Proteins and Vaccine Candidates
Kanjo, K., Lothe, R. R., Nagar, G., Rajurkar, M. P., Rao, H. D., Batwal, S., Shaligram, U. S., & Varadarajan, R. (2025) · Vaccines · doi:10.3390/vaccines13040395 · Cited by 2
Immunization update 2018
Angelo, L. B. (2018) · Pharmacy Today · doi:10.1016/j.ptdy.2018.08.030 · Cited by 2
Sexually Transmitted Diseases in Adolescents: Viral Hepatitis
Kalapila, A. G., & Dhanireddy, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-20491-4_19 · Cited by 2
Seroconversion following Heplisav-B, hepatitis B vaccine (recombinant), adjuvanted, in patients with end-stage renal disease at an urban safety net hospital
Walsh, C. D., McDaniel, K. N., Lindsey, L., Johnson, S., & Walton, T. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad022 · Cited by 2
Novel approaches in the medical management of compensated cirrhosis
Moreno-Loro, A., Gallego, Á. G., Jiménez, F., López-Bueno, I., Pérez-Ramírez, A., & Romero‐Gómez, M. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2358149 · Cited by 1
Maternal Immunization
Jamieson, D. J., Muñoz, F. M., & Rasmussen, S. A. (2026) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000006243 · Cited by 1
Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
Hegde, Y. D., & Caldera, F. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70651 · Cited by 1
Don't Drop the B: Risk of Hepatitis B Virus Infection and Reactivation in the Era of Tenofovir-Sparing Regimens for Treatment and Prevention of Human Immunodeficiency Virus
Lee, T.-H., Bhattacharya, D., & Kim, H. N. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag322 · Cited by 1
Protein-directed nucleotide selection in the DRT3 defense system: mechanism, biological context, and constraints on programmability
Niazi, S. K. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1866040 · Cited by 1
Serological evidence of hepatitis B virus exposure and vaccination coverage trends in health sciences students in Albania
Jaho, J., Balilaj, L., Bulla, A., Capraro, Y., Lamfu, L., & Baiocchi, L. (2026) · World Journal of Virology · doi:10.5501/wjv.v15.i2.118992 · Cited by 1
Long-term protection following a primary series of hepatitis B vaccine in Alaska Native children and adults
Steinberg, J., Blake, I., Stevenson, T. J., Wheelock, H., Bruden, D. J. T., Townshend‐Bulson, L., Klejka, J. A., Peterson, M., Cartwright, E. J., Drobeniuc, J., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000978 · Cited by 1
Variations in Hepatitis B Vaccine Series Completion by Setting Among Adults at Risk in West Virginia
Tressler, S. R., Lilly, C. L., Gross, D., Hulsey, T. C., & Feinberg, J. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2020.05.022 · Cited by 1
Hepatitis B vaccine and risk of acute myocardial infarction among individuals with diabetes mellitus
Wong, K., Bruxvoort, K. J., Slezak, J. M., Hsu, J. Y., Reynolds, K., Sy, L. S., & Jacobsen, S. J. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5327 · Cited by 1
Transplanting Kidneys From Donors With Chronic Hepatitis B: Bringing Transmission Risk Closer to Zero
Terrault, N. A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa172 · Cited by 1
Prevention and Management of HBV in Organ Transplantation
Celaj, S., & Levitsky, J. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00537-7 · Cited by 1
Adolesan Çocuklarda Hepatit B Belirteçlerinin İncelenmesi-Düzce Üniversitesi Hastanesi 5 Yıllık Sonuçlar
Kılıçaslan, Ö., Sav, N. M., Karaca, S. E., Sungur, M. A., Öztürk, C. E., & Kocabay, K. (2021) · Sağlık Bilimlerinde Değer · doi:10.33631/duzcesbed.824589 · Cited by 1
Hepatitis B Virus Screening and Vaccination in Patients With HIV: A Survey of Clinicians’ Current Practices
Hastie, E., & Wooten, D. A. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab270 · Cited by 1
Infectious Diseases
Coonrod, D. V., & Bailey, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-31753-9_11 · Cited by 1
Outcome of Infants Born to Women with Chronic Hepatitis B: A Local Risk-Based Strategy in a Low Prevalence Country
Giannina Izquierdo, C., Ibáñez, C., Piñera, C., Cordova, L., Payá, E., Leal, P., & Villena, R. (2024) · Maternal and Child Health Journal · doi:10.1007/s10995-024-03909-3 · Cited by 1
Analysis of Hepatitis B and C Seroprevalence and Anti-Hbs Antibody Titers in Type 2 Diabetic Patients with and without Diabetic Foot Ulcers
Karaaslan, H., & KESKİN, C. (2024) · Harran Üniversitesi Tıp Fakültesi Dergisi · doi:10.35440/hutfd.1464459 · Cited by 1
Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases?
Гриднева, Г. И., Belov, B. S., & Aronova, E. S. (2024) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2024-5-121-126 · Cited by 1
Updates in Adult Immunizations
Maltz, F. N., & Fidler, B. D. (2019) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.10.012 · Cited by 1
Human Papillomavirus, Herpes Zoster, and Hepatitis B Vaccinations in Immunocompromised Patients: An Update for Pharmacists
Paulsen, M. R., Patel, N. R., Sulis, C., Farraye, F. A., & Bhat, S. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020958261 · Cited by 1
Pretransplant Screening for Infection Exposure: Approach to the Patients with Epidemiologic and Geographic Risk Factors
Nanayakkara, D. D., & Schaenman, J. M. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-01751-4_9-1 · Cited by 1
Hepatitis B and Hepatitis D Infections in the Transplant Setting
Kim, B. S., & Terrault, N. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-25869-6_37 · Cited by 1
Vaccine recommendations in pregnancy and lactation
Taylor, C. M., & Shelton, C. M. (2018) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2018.12.001
The 2019 immunization schedules for children, adolescents and adults. What’s New?
Sampathkumar, P., & Poland, G. A. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.05.001
Third Time’s a Charm: Immunization Strategies for Hepatitis B in Immunosuppressed Patients with Inflammatory Bowel Disease
Ley, D., Hayney, M. S., & Caldera, F. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05662-y
Immunization update 2019
Wilhelm, M. (2019) · Pharmacy Today · doi:10.1016/j.ptdy.2019.05.026
2018-2019 ACIP Immunization Updates: Highlights for Pharmacists
Bethishou, L., Munjy, L., & Goad, J. A. (2019) · Chapman University Digital Commons (Chapman University)
Hepatitis B and Hepatitis D Infections in the Transplant Setting
Kim, B. S., & Terrault, N. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-01751-4_37-1
Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases
Pombo‐Suárez, M., & Gómez-Reino, J. J. (2020) · Technical report · doi:10.1016/b978-0-444-64217-2.00009-9
Hepatitis B vaccine failures: how do we handle them?
Shouval, D. (2020) · Wiley eBooks · doi:10.1002/9781119533481.ch30
Hepatitis B in At-Risk Groups: Three Studies to Guide Education, Testing, and Vaccination Efforts in West Virginia
Tressler, S. R. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7625
Infections in the solid-organ transplant recipients
Said, M. E. (2021) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.2(70).2021.08
Optimizing hepatitis B prevention and control
Raven, S. F. H. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20211001cr
Pretransplant Screening for Infection Exposure: Approach to the Patients with Epidemiologic and Geographic Risk Factors
Nanayakkara, D. D., & Schaenman, J. M. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-25869-6_9
Hepatitis B
Dudley, M. Z., Salmon, D. A., Halsey, N. A., Orenstein, W. A., Limaye, R. J., O’Leary, S. T., & Omer, S. B. (2018) · Springer eBooks · doi:10.1007/978-3-319-94694-8_9
Chapter 10: Prevention of Pregnancy and Sexually Transmitted Infections
El‐Ibiary, S. Y., & Raney, E. C. (2020) · The American Pharmacists Association eBooks · doi:10.21019/9781582123172.ch10
Hepatitis Viruses: Hepatitis B and Hepatitis D
Cohen, C. A., Evans, A. A., & Block, T. M. (2022) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_32-1
Active Immunization
Kroger, A. T., Robinson, C. L., Pickering, L. K., & Orenstein, W. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00006-9
Hepatitis Viruses: Hepatitis B and Hepatitis D
Cohen, C. A., Evans, A. A., & Block, T. M. (2023) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_32-2
Vaccines for International Travel
Barnett, E. D., Kozarsky, P. E., & Steffen, R. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00071-2
CHRONIC HEPATITIS B VIRUS INFECTION: WHERE WE ARE NOW
", Rotarescu, C. A., del Campo, M. G. M., & Mărunțelu, I. (2022) · Romanian Archives of Microbiology and Immunology · doi:10.54044/rami.2022.03.05
Hepatitis B Triple Panel Testing Implementation in the Obstetric Care Setting: Unique Predictors of Hepatitis B Virus Vaccine Immunity, Exposure, and Positivity
Schmidt, N., Rios, J., Alpert, L., Mageras, A., Lieb, W., & Kushner, T. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae632
Hepatitis B Vaccination Status, Knowledge, and Attitudes among Healthcare Workers in Military Hospital, Khartoum State: A Cross-sectional Study
Yahia, S., Babiker, S., Mohamed, M. G., Ahmed, A. H., Babiker, A. A. A.-A., Altayeb, E. A., Hassan, H. G., Maisra, M., & Saeed, A. A. (2024) · Matrix Science Pharma · doi:10.4103/mtsp.mtsp_8_24_1
Do children with type 1 diabetes mellitus remain protected against hepatitis B?
Yılmazbaş, N. P., Bezen, D., & Vurgun, E. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0520
Active Immunizing Agents
Dennehy, P. H., Holland, S., Köster, M., & Rogo, T. O. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00262-4
Molecular ingredients of an immunogen for long-lasting IgG
Gupta, S. L., Meyer, A. R., Kay-Tsumagari, E., & Cheng, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639371
Unmasking the alphabets: Comprehensive introduction to hepatitis A to E virus infections
Vignesh, R., & Balakrishnan, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29005-3.00001-0
Hepatitis Viruses: Hepatitis B and Hepatitis D
Cohen, C. A., Evans, A. A., & Block, T. M. (2025) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_32-3
Additional file 1 of Could eggshell membrane be an adjuvant for recombinant Hepatitis B vaccine?: A preliminary investigation
Joshua, P. E., Ilo, C. C., Ukachukwu, U. G., Odimegwu, D. C., Asomadu, R. O., & Ezeorba, T. P. C. (2024) · Figshare · doi:10.6084/m9.figshare.26580533
Additional file 1 of A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Kumari, M., Lu, R.-M., Li, M.-C., Huang, J., Hsu, F.-F., Ko, S.-H., Ke, F.-Y., Su, S.-C., Liang, K.-H., Yuan, J. P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21085242
Implementation of New Guidelines and Vaccines for the Prevention of Acute and Chronic HBV Infection
Lai, H. X., Tan, Y. C., & Lim, S. G. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00715-5
Hepatitis B Vaccination Coverage and Its Determinants Among Healthcare Personnel in Chengalpattu District: A Cross-Sectional Study
Anushuya, M., Raja, D., Sridharan, V., Meena, D., & Ramesh, P. (2026) · Cureus · doi:10.7759/cureus.106638

Authors: Schillie, S., Harris, A., Link-Gelles, R., Romero, J., Ward, J., & Nelson, N.
Affiliations: Arkansas Children's Hospital (US)
Corresponding author: Schillie, Sarah
ORCID: Schillie, Sarah
Harris, Aaron
Ward, John
Nelson, Noele
Venue: MMWR Morbidity and Mortality Weekly Report
Publisher: Centers for Disease Control MMWR Office
Published: 2018-04-20
Volume: 67
Issue: 15
Pages: 455-458
ISSN: 0149-2195 (ISSN-L)
1545-861X
DOI: 10.15585/mmwr.mm6715a5
PMC: PMC6191098
OpenAlex: W2800687120
Cited by: 208
References: 9
Citations by year: 2026: 16 · 2025: 15 · 2024: 19 · 2023: 21 · 2022: 25 · 2021: 37 · 2020: 42 · 2019: 25 · 2018: 8
FWCI: 21.84
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: MMWR Morbidity and Mortality Weekly Report (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: U.S. Department of Health and Human Services
University of Arkansas
University of Arkansas for Medical Sciences
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Topics: Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords: hepatitis B vaccine, CpG adjuvant, hepatitis B prevention, adult vaccination, seroprotection, anti-HBs antibodies, vaccine adverse events, Engerix-B, Advisory Committee on Immunization Practices recommendations
MeSH terms: Adjuvants, Immunologic, Adolescent, Adult, Centers for Disease Control and Prevention, U.S., Hepatitis B, Humans, Immunization Schedule, United States, Randomized Controlled Trials as Topic, Hepatitis B Vaccines, Practice Guidelines as Topic, Advisory Committees

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks